Dr. Sidor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
101 Manning Dr
Chapel Hill, NC 27599Phone+1 919-966-4996Fax+1 919-843-5515- Is this information wrong?
Education & Training
- Main Line Health System/Lankenau Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1988
- Sidney Kimmel Medical College at Thomas Jefferson University/Christiana Care Health ServicesResidency, Internal Medicine, 1982 - 1985
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1982
Certifications & Licensure
- NC State Medical License 1993 - 2024
- DE State Medical License 1985 - 2013
- PA State Medical License 1985 - 2012
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Start of enrollment: 2014 Jan 01
Publications & Presentations
PubMed
- 23 citationsA phase I trial of the aurora kinase inhibitor , ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemiaKaren W.L. Yee, Hsiao-Wei T. Chen, David W. Hedley, Sue Chow, Joseph Brandwein, Andre C. Schuh, Aaron D. Schimmer, Vikas Gupta, Deborah Sanfelice, Tara Johnson, Lisa W...> ;Investigational New Drugs. 2016 Jul 12
- 33 citationsENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancerUrsula A. Matulonis, Julie Lee, Brian Lasonde, William P. Tew, Afra Yehwalashet, Daniela Matei, Kian Behbakht, Jill Grothusen, Gini F. Fleming, Nita K. Lee, Jamie Arno...> ;European Journal of Cancer. 2013 Jan 1
- 12 citationsPhase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) ...Amye J. Tevaarwerk, George Wilding, Jens C. Eickhoff, Rick Chappell, C. Sidor, Jamie Arnott, Howard H. Bailey, William R. Schelman, Glenn Liu> ;Investigational New Drugs. 2012 Jun 1
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: